Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.74 |
| ▸ | CNR2 | P34972 | 6/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 2/20 | 0.51 |
| ▸ | FLT4 | P35916 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16340085 | 1.00 | CNR1 (0.74) | CNR1CNR2CA1CA2FLT1 | |
| SCHEMBL17247322 | 0.91 | CNR1 (0.63) | CNR1CNR2CA1CA2 | |
| SCHEMBL17150867 | 0.88 | CNR1 (0.73) | CNR1CNR2CA1CA2PDE5A | |
| SCHEMBL16339982 | 0.88 | CNR1 (0.73) | CNR1CNR2CA1CA2PDE5A | |
| SCHEMBL3560023 | 0.88 | CNR1 (0.77) | CNR1CNR2CA1CA2FLT1 | |
| SCHEMBL3561680 | 0.85 | CNR1 (1.00) | CNR1CNR2CA1CA2 | |
| SCHEMBL3562624 | 0.83 | CNR1 (0.75) | CNR1CNR2CA1CA2L3MBTL1 | |
| SCHEMBL3562619 | 0.83 | CNR1 (0.76) | CNR1CNR2CA1CA2ALDH1A1 | |
| SCHEMBL16340252 | 0.81 | CNR1 (0.65) | CNR1CNR2CA1CA2PDE5A | |
| SCHEMBL1023193 | 0.81 | CNR1 (0.58) | CNR1CNR2CA1CA2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015152550-A1 | 4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXIMIDAMIDE DERIVATIVES CONTAINING SULFUR GROUPS, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HANMI PHARM. CO., LTD. (KR) | 2015-10-08 | — | — | WO | disclosed |
| WO-2014208939-A1 | 1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONIST, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HANMI PHARM. CO., LTD. (KR) | 2014-12-31 | — | — | WO | disclosed |
| US-7745476-B2 | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-06-29 | — | — | US | disclosed |
| CN-100563651-C | With CB1-antagonistic activity of 1 | SOLVAY PHARM BV (NL) | 2009-12-02 | — | — | CN | disclosed |
| EP-1713475-B1 | 1,3,5-TRISUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-07-30 | — | — | EP | disclosed |
| CN-1913885-A | With CB1Antagonistic 1,3, 5-trisubstituted 4, 5-dihydro-1H-pyrazole derivatives | SOLVAY PHARM BV (NL) | 2007-02-14 | — | — | CN | disclosed |
| EP-1713475-A1 | 1,3,5-TRISUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005074920-A1 | 1,3,5-TRISUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-08-18 | — | — | WO | disclosed |
| US-20050171179-A1 | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171179-A1 | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | CNR2, CNR1, TBXA2R | CNR1 2/4885CNR2 1/4885CA1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.